Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 15, Issue 3, Pages 151-167
Publisher
Springer Nature
Online
2017-11-14
DOI
10.1038/nrclinonc.2017.175
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study
- (2017) Alain Ravaud et al. EUROPEAN JOURNAL OF CANCER
- Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study
- (2017) Jes Sloth Mathiesen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
- (2017) Oliver Gautschi et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- (2017) Jean-Charles Soria et al. LANCET
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling
- (2017) Sarah K. Nelson-Taylor et al. MOLECULAR CANCER THERAPEUTICS
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
- (2017) Dennis Plenker et al. Science Translational Medicine
- EGF Induced RET Inhibitor Resistance inCCDC6-RETLung Cancer Cells
- (2017) Hyun Chang et al. YONSEI MEDICAL JOURNAL
- Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
- (2017) Kiyotaka Yoh et al. Lancet Respiratory Medicine
- What hides behind the MASC: clinical response and acquired resistance to entrectinib afterETV6-NTRK3identification in a mammary analogue secretory carcinoma (MASC)
- (2016) A. Drilon et al. ANNALS OF ONCOLOGY
- Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung
- (2016) V. Velcheti et al. ANNALS OF ONCOLOGY
- Clinical outcomes with pemetrexed-based systemic therapies inRET-rearranged lung cancers
- (2016) A. Drilon et al. ANNALS OF ONCOLOGY
- Correlative analyses ofRETand RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer
- (2016) Steven I. Sherman et al. CANCER
- Abstract 2641: The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors
- (2016) Rami Rahal et al. CANCER RESEARCH
- Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations
- (2016) Gang G. Li et al. CLINICAL CANCER RESEARCH
- RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
- (2016) Shumei Kato et al. CLINICAL CANCER RESEARCH
- Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression
- (2016) Joel Smith et al. HUMAN MOLECULAR GENETICS
- Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer
- (2016) Jessica J. Lin et al. Journal of Thoracic Oncology
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer
- (2016) Atsushi Horiike et al. LUNG CANCER
- Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma
- (2016) Q. Huang et al. MOLECULAR CANCER THERAPEUTICS
- Glial-cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence
- (2016) Sales Ibiza et al. NATURE
- A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
- (2016) Cristina Romei et al. Nature Reviews Endocrinology
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
- (2016) E. J. Brea et al. Cancer Immunology Research
- First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
- (2015) Y.-L. Wu et al. ANNALS OF ONCOLOGY
- A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies
- (2015) Adam Platt et al. BMC CANCER
- A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
- (2015) M. Schlumberger et al. CLINICAL CANCER RESEARCH
- Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
- (2015) A. Drilon et al. CLINICAL CANCER RESEARCH
- An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
- (2015) Sun Min Lim et al. EUROPEAN JOURNAL OF CANCER
- RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma
- (2015) Elizabeth G. Grubbs et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer
- (2015) Sarayut L Geater et al. Journal of Thoracic Oncology
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases
- (2015) Vivek Subbiah et al. LUNG CANCER
- Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer
- (2015) Silvia Martina Ferrari et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Abstract B192: Identification and characterization of highly potent and selective RET kinase inhibitors for the treatment of RET-driven cancers
- (2015) Barbara J. Brandhuber et al. MOLECULAR CANCER THERAPEUTICS
- RET gene is a major risk factor for Hirschsprung’s disease: a meta-analysis
- (2015) C. Tomuschat et al. PEDIATRIC SURGERY INTERNATIONAL
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
- (2015) Samuel A. Wells et al. THYROID
- Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
- (2015) Parag P. Patwardhan et al. Oncotarget
- Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer
- (2015) Jun Ho Ji et al. PLoS Genetics
- Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase
- (2015) Marialuisa Moccia et al. PLoS One
- RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
- (2014) K Tsuta et al. BRITISH JOURNAL OF CANCER
- A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis
- (2014) Motonobu Saito et al. CARCINOGENESIS
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma
- (2014) Nishant Agrawal et al. CELL
- Mechanisms of RET signaling in cancer: Current and future implications for targeted therapy
- (2014) I. Plaza-Menacho et al. CELLULAR SIGNALLING
- Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
- (2014) T. Nakaoku et al. CLINICAL CANCER RESEARCH
- Inhibition of RET Increases the Efficacy of Antiestrogen and Is a Novel Treatment Strategy for Luminal Breast Cancer
- (2014) P. M. Spanheimer et al. CLINICAL CANCER RESEARCH
- A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer
- (2014) Maruja E. Lira et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Mutations in 12 known dominant disease-causing genes clarify many congenital anomalies of the kidney and urinary tract
- (2014) Daw-Yang Hwang et al. KIDNEY INTERNATIONAL
- Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non-Small Cell Lung Cancer
- (2014) T. Kodama et al. MOLECULAR CANCER THERAPEUTICS
- The neurotrophic factor receptor RET drives haematopoietic stem cell survival and function
- (2014) Diogo Fonseca-Pereira et al. NATURE
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease
- (2014) Janan T. Eppig et al. NUCLEIC ACIDS RESEARCH
- The landscape and therapeutic relevance of cancer-associated transcript fusions
- (2014) K Yoshihara et al. ONCOGENE
- A novel RET rearrangement (ACBD5/RET) by pericentric inversion, inv(10)(p12.1;q11.2), in papillary thyroid cancer from an atomic bomb survivor exposed to high-dose radiation
- (2014) KIYOHIRO HAMATANI et al. ONCOLOGY REPORTS
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
- (2014) Thomas Wiesner et al. Nature Communications
- KIF5B-RETfusions in Chinese patients with non-small cell lung cancer
- (2013) Weijing Cai et al. CANCER
- RET/PTCandPAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics
- (2013) Rebecca J. Leeman-Neill et al. CANCER
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
- (2013) Kiyoshi Okamoto et al. CANCER LETTERS
- GDNF-RET Signaling in ER-Positive Breast Cancers Is a Key Determinant of Response and Resistance to Aromatase Inhibitors
- (2013) A. Morandi et al. CANCER RESEARCH
- Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitorsin vitroandin vivo
- (2013) Makito Suzuki et al. CANCER SCIENCE
- Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
- (2013) E. Fox et al. CLINICAL CANCER RESEARCH
- Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells
- (2013) Matti L Gild et al. ENDOCRINE-RELATED CANCER
- Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia
- (2013) Nitin Jain et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
- (2013) Luca Mologni et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies
- (2013) Daniela Bossi et al. Molecular Oncology
- Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
- (2013) M. E. Lacouture et al. ONCOLOGIST
- In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
- (2013) Frauke Bentzien et al. THYROID
- Central Role of RET in Thyroid Cancer
- (2013) M. Santoro et al. Cold Spring Harbor Perspectives in Biology
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- Structural studies of GDNF family ligands with their receptors—Insights into ligand recognition and activation of receptor tyrosine kinase RET
- (2012) Xinquan Wang BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Traditional and targeted exome sequencing reveals common, rare and novel functional deleterious variants in RET-signaling complex in a cohort of living US patients with urinary tract malformations
- (2012) Rajshekhar Chatterjee et al. HUMAN GENETICS
- Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)
- (2012) Jin Soo Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
- (2012) Ji-Youn Han et al. JOURNAL OF CLINICAL ONCOLOGY
- RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
- (2012) Rui Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad
- (2012) Daisuke Matsubara et al. Journal of Thoracic Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation
- (2012) P Ballerini et al. LEUKEMIA
- Chipping away at the lung cancer genome
- (2012) William Pao et al. NATURE MEDICINE
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- KIF5B-RET fusions in lung adenocarcinoma
- (2012) Takashi Kohno et al. NATURE MEDICINE
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Differential RET Signaling Pathways Drive Development of the Enteric Lymphoid and Nervous Systems
- (2012) A. Patel et al. Science Signaling
- VEGF Inhibition, Hypertension, and Renal Toxicity
- (2012) Suzanne R. Hayman et al. Current Oncology Reports
- The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells
- (2011) Chunyu Wang et al. BREAST CANCER RESEARCH AND TREATMENT
- The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells
- (2011) Hans H. G. Verbeek et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predicting Phenotypic Severity of Uncertain Gene Variants in the RET Proto-Oncogene
- (2011) David K. Crockett et al. PLoS One
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
- (2011) Mario E. Lacouture et al. SUPPORTIVE CARE IN CANCER
- Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
- (2010) L. L. Carr et al. CLINICAL CANCER RESEARCH
- The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells
- (2010) D. Vitagliano et al. ENDOCRINE-RELATED CANCER
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
- (2010) Elaine T. Lam et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
- (2010) Roy S Herbst et al. LANCET ONCOLOGY
- Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC
- (2010) Karin Frank-Raue et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells
- (2010) M Gandhi et al. ONCOGENE
- Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance
- (2010) I Plaza-Menacho et al. ONCOGENE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effects of Silencing RET/PTC1 Junction Oncogene in Human Papillary Thyroid Carcinoma Cells
- (2010) Marie Gilbert-Sirieix et al. THYROID
- Multiple Endocrine Neoplasia Type 2B with a RET Proto-Oncogene A883F Mutation Displays a More Indolent Form of Medullary Thyroid Carcinoma Compared with a RET M918T Mutation
- (2010) Sina Jasim et al. THYROID
- Transcript Level Modulates the Inherent Oncogenicity of RET/PTC Oncoproteins
- (2009) D. S. Richardson et al. CANCER RESEARCH
- Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy
- (2009) N. S. Azad et al. CLINICAL CANCER RESEARCH
- Ret-Dependent Cell Rearrangements in the Wolffian Duct Epithelium Initiate Ureteric Bud Morphogenesis
- (2009) Xuan Chi et al. DEVELOPMENTAL CELL
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
- (2009) Martin J. Schlumberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- RET/PTC-Induced Cell Growth Is Mediated in Part by Epidermal Growth Factor Receptor (EGFR) Activation: Evidence for Molecular and Functional Interactions between RET and EGFR
- (2008) M. Croyle et al. CANCER RESEARCH
- The Ret Receptor Tyrosine Kinase Pathway Functionally Interacts with the ER Pathway in Breast Cancer
- (2008) A. Boulay et al. CANCER RESEARCH
- Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy
- (2008) Yohann Loriot et al. Nature clinical practice. Oncology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More